CardioMech is a brand dedicated to designing innovative therapeutic options for heart disease. With a focus on the percutaneous approach, CardioMech is developing a catheter-based mitral valve repair technology that offers a promising solution for patients suffering from moderate to severe or severe, symptomatic DMR (Degenerative Mitral Regurgitation) caused by prolapse or flail. The cutting-edge CardioMech technology aims to provide a catheter-based therapy by placing artificial chord(s) to reduce or even eliminate MR (Mitral Regurgitation), serving as an effective alternative to surgical mitral valve repair.

It is important to note that the CardioMech device is currently in the early stages of research and development and has not yet obtained approval or clearance from the FDA or any other regulatory body in any region of the world. For more information, potential partners and general inquiries, please reach out to CardioMech at info@cardiomech. com.

CardioMech is based in Trondheim, Norway, and strives to revolutionize heart disease treatment. All rights reserved by CardioMech AS